Alpine Associates Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Alpine Associates Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,349,966	Closed	-$7.14M	–	59
2024 Q4	$7.14M	Sell	2,349,966 -1,812,895	-44%	-$7.9M	0.43%	38
2024 Q3	$21.6M	Buy	+4,162,861	New	+$20.7M	0.99%	32

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Alpine Associates Management's RVNC Position: Q1 2025 in Review

Alpine Associates Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 2,349,966 shares — an estimated $7.14M sold.

Alpine Associates Management first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $21.6M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Alpine Associates Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Alpine Associates Management sold 2,349,966 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $7.14M.
Alpine Associates Management first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
Alpine Associates Management's Revance Therapeutics, Inc. position peaked at $21.6M in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Alpine Associates Management's 13F filing for Q1 2025, filed 8 May 2025.